|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Phenotype variability in tumor disorders of the skin appendages associated with mutations in the CYLD gene.
|
29974194 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
These include deletion of the tumor suppressor CYLD, promotor methylation of the Wnt antagonists WIF1, DKK1, DKK3, and sFRP1, sFRP2, sFRP4, sFRP5, as well as overexpression of the co-transcriptional activator BCL9 and the R-spondin receptor LGR4.
|
30770859 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction.
|
19917957 |
2009 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Patients with germline mutations in a tumour suppressor gene called CYLD develop multiple, disfiguring, hair follicle tumours on the head and neck.
|
28270164 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Pathogenic truncations of the CYLD C terminus, associated with the hypertrophic skin tumor cylindromatosis, disrupt the USP domain, accounting for loss of CYLD catalytic activity.
|
18313383 |
2008 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In affected families, mutations have been demonstrated in the CYLD gene located on chromosome 16q12-13 and reveal the characteristic attributes of a tumor suppressor.
|
12190880 |
2002 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
RNA interference-mediated silencing of TRKB and TRKC, as well as treatment with the small-molecule TRK inhibitor lestaurtinib, reduced colony formation and proliferation in 3D primary cell cultures established from CYLD mutant tumours.
|
21552290 |
2011 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In 1 patient only with 2 spiradenomas, both tumors harbored identical CYLD sequence alterations (c.1112C>A/S371X) in the CYLD gene and both showed loss of heterozygosity on chromosome 16q.
|
22588548 |
2013 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We conclude that somatic mutation of the CYLD1 gene outside the skin can have a role in the oncogenesis of tumors with cylindromatous features.
|
11756779 |
2002 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
A predisposition to multiple cylindromas is seen in patients with Brooke-Spiegler syndrome, who carry germline mutations in the tumour suppressor gene CYLD.
|
26969893 |
2016 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Recurrent mutations were identified in tumor suppressor genes TP53 (n = 4), SMAD4 (n = 2), and CYLD (n = 2); and chromatin remodeling genes KDM6A (n = 3), SETD2 (n = 2), MLL3 (n = 2), and MLL2 (n = 2).
|
25299233 |
2015 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Germline mutations in the tumour suppressor gene CYLD are recognized to be associated with the development of multiple cutaneous cylindromas.
|
29569226 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes.
|
31624251 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
DNA analysis of tumour tissue showed loss of heterozygosity for the cylindromatosis CYLD1 locus.
|
9783709 |
1998 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
They are now known to occur on an inherited basis as a result of mutations in the tumor-suppressor gene CYLD.
|
27890238 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
These neoplasms also share considerable phenotypic resemblance and co-exist with certain dermal adnexal tumors harboring the CYLD gene mutations inferring common genetic association.
|
29463883 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Using these data, we propose a model where epigenetic programming may influence tumour patterning in patients with CYLD mutations.
|
21598248 |
2011 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Of these potential substrates, serine 418 of the tumor suppressor CYLD was identified as a likely site of IKKepsilon phosphorylation.
|
19481526 |
2009 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In this manuscript we report that the tumor suppressor CYLD, similarly to other renowned tumor suppressor genes, protects from premature aging and cancer.
|
30631004 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
This observation suggests that the cyld1 gene may be the only tumour suppressor gene implicated in the development of cylindromas.
|
8649842 |
1996 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD lysine 63 deubiquitinase (CYLD) was originally identified as a tumor suppressor that is mutated in familial cylindromatosis.
|
29344161 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
To elucidate how CYLD contributes to tumor formation, we aimed to identify molecular partners in keratinocytes.
|
31260673 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The loss of CYLD gene of tumor suppressor gene, 16q12-q13, was only on locus of common involvement in 3 cell lines.
|
18799932 |
2008 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
For this, we explored the tumor microenvironment for targeted drug delivery and synthesized (temperature and pH responsive) double triggered polymeric nanoparticles by the free radical mechanism and characterized them by DLS and TEM.
|
31549130 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In addition, we delineate how CYLD interferes with activation of the proto-oncogene Bcl(3) and with cyclin D1 expression to limit tumorigenesis, and chart how tumor growth-promoting agents or UV light and inflammatory mediators can activate CYLD.
|
18008375 |
2007 |